---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107833"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:22:15.392846+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics issues $182,400 convertible note to Vanquish Funding

## Summary
- Issued $182,400 promissory note (incl. $22,400 OID) to Vanquish Funding; net proceeds ~$155,000 after $5,000 fees.
- Note bears 12% interest (22% if unpaid), matures August 30, 2026; convertible at 35% discount to lowest 10-day trading price.
- Additional tranches up to $2M available over 12 months subject to further agreement with Vanquish.
- Conversion shares subject to 4.99% beneficial ownership cap; issued under Section 4(a)(2) exemption.
- Proceeds will be used for general working capital purposes.

## SEC filing metadata
- accession: 0001104659-25-107833
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465925107833/0001104659-25-107833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465925107833/tm2530384d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107833
- JSON: https://secwatch.observer/filing/0001104659-25-107833.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107833.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.